等待开盘 09-11 09:30:00 美东时间
-0.610
-2.51%
今日重点评级关注:Ascendiant Capital:维持PAVmed"买入"评级,目标价从56美元升至57美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从9.25美元升至9.5美元
08-28 16:15
亮眼财报成“吸金石”!爱芬奇绩后飙升35.7%,全年EPS指引上调至最高13.6美元;BOSS直聘升近16%,宣布2.3亿美元派息计划;Biohaven劲升17.9%,获7.95亿美元许可协议。
08-27 15:41
Prenetics Global (PRE) announced on Wednesday that Danny Yeung, chief executive officer, and Brian Rosin, chief financial officer, completed open market purchases of its ordinary shares during the pe...
08-26 20:57
Prenetics Global (NASDAQ:PRE) sees FY2026 sales of $220.000 million-$230.000 million vs $214.071 million analyst estimate.
08-18 19:40
Prenetics Global (NASDAQ:PRE) sees Q3 sales of $63.000 million-$64.000 million vs $59.310 million analyst estimate.
08-18 19:40
Prenetics Global (NASDAQ:PRE) initiates FY2027 guidance of $400 million+ in IM8 revenue.
08-18 19:35
Prenetics Global (NASDAQ:PRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent. This is a 35.37 percent increase over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $46.488 millio...
08-18 19:34
Prenetics reported Q2 2026 revenue of $46.5 million, up 288% YoY, with IM8 contributing $45 million, up 359% YoY. July marked IM8's strongest month at $20.9 million, annualizing to $251 million. The company raised FY2026 revenue guidance to $220-$230 million and initiated FY2027 IM8 guidance of $400 million+. CEO Danny Yeung highlighted the sixth consecutive record quarter, positive Adjusted Free Cash Flow, and a new reporting approach with detai...
08-18 11:30
今日重点评级关注:Needham:维持Annexon"买入"评级,目标价从11美元升至25美元;Benchmark:维持Prenetics Global"买入"评级,目标价从30美元升至40美元
07-16 18:55
华尔街称“存储荒”将持续数年!SK海力士劲升27%,美股ADR较韩股溢价4成;ATAI升逾14%,迷幻药开发公司获政策利好;PRE升逾13%,获10亿美元增长融资>>
07-15 18:56